ReCode Therapeutics - Raised $342M Funding from 20 investors

5 days ago · yiliaomsl.cn - raised a funding in Series A round held on 25 Oct, 2024. ReCode Therapeutics has raised a total funding of $342M over 6 rounds from 20 investors. Investors …

CouponFollow Extension

$342
OFF

ReCode Therapeutics - Raised $342M Funding From 20 Investors

1 week from now

5 days ago · yiliaomsl.cn - raised a funding in Series A round held on 25 Oct, 2024. ReCode Therapeutics has raised a total funding of $342M over 6 rounds from 20 investors. Investors …

tracxn.com

$342
OFF

ReCode Therapeutics - Company Profile - Tracxn

1 week from now

5 days ago · ReCode Therapeutics - Developer of precision medicines for treating lung related diseases. Raised a total funding of $342M over 6 rounds from 20 investors. Valued at $372M. …

tracxn.com

$342
OFF

ReCode Therapeutics - Raised $342M Funding From 20 Investors …

1 week from now

ReCode Therapeutics has raised a total funding of $342M over 6 rounds from 20 investors. Investors include Pfizer Venture Investments, MPM Capital and 18 others. Their latest funding …

tracxn.com

$120
OFF

ReCode Breaks The Mold With $120M Financing, Big Pharma Backing

1 week from now

Jun 29, 2022 · ReCode breaks the mold with $120M financing, bringing clutch of Big Pharmas along for ride. ReCode Therapeutics has stuck to a formula of $80 million funding rounds, but, …

fiercebiotech.com

$260
OFF

ReCode Therapeutics Announces Closing Of Extension To Series B ...

1 week from now

Sep 19, 2023 · Total of $260 million in Series B funding includes an additional $50 million from existing and new investors, Bioluminescence Ventures and Solasta Ventures September 19, …

businesswire.com

$50
OFF

Foley Represents Bioluminescence Ventures As Lead Investor In ReCode …

1 week from now

Sep 27, 2023 · Foley & Lardner LLP represented Bioluminescence Ventures as the lead investor in the $50 million Series B funding extension for ReCode Therapeutics, a clinical-stage genetic …

foley.com

$120
OFF

SORTing It Out: ReCode Expands Beyond Respiratory Disorders

1 week from now

Jul 5, 2022 · ReCode Therapeutics CEO ... The expanded Series B adds $120 million to the $80 million that ReCode raised in its initial second round last fall. ... The funding will also allow …

genengnews.com

FAQs about ReCode Therapeutics - Raised $342M Funding from 20 investors Coupon?

How much money has Recode Therapeutics raised?

ReCode Therapeutics has raised $342M. Who are ReCode Therapeutics’s investors? AJU IB Investment, Amgen Ventures, Ayur Maya, Bioluminescence Ventures, and Blockchange Ventures are 5 of 22 investors who have invested in ReCode Therapeutics. ...

How many investors does Recode therapeutics have?

Recode Therapeutics has 18 investors. OrbiMed Advisors invested in Recode Therapeutics's Series B - IV funding round. Recode Therapeutics acquired 1 company. Their latest acquisition was TranscripTx on April 01, 2020. ...

Does Recode therapeutics have a series B?

ReCode Therapeutics has stuck to a formula of $80 million funding rounds, but, thanks to investments from the venture arms of Bayer and Amgen, the genetic medicine and mRNA biotech is breaking the mold with a $120 million extended series B. ...

Who is Recode Therapeutics?

About ReCode Therapeutics ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. ...

When did Recode Therapeutics close?

ReCode Therapeutics closed its last funding round on Sep 19, 2023 from a Series B round. Who are ReCode Therapeutics's competitors? Alternatives and possible competitors to ReCode Therapeutics may include Syros Pharmaceuticals , NephroDI Therapeutics , and Aclaris Therapeutics. ...

What are the alternatives to recode Therapeutics?

Alternatives and possible competitors to ReCode Therapeutics may include Syros Pharmaceuticals , NephroDI Therapeutics , and Aclaris Therapeutics. ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics. ...